<DOC>
	<DOCNO>NCT01174030</DOCNO>
	<brief_summary>The purpose vehicle control study evaluate efficacy safety CD07805/47 gel 0.5 % apply topically daily ( QD ) 4 week , CD07805/47 gel 0.18 % apply topically daily ( QD ) twice daily ( BID ) 4 week , subject moderate severe facial erythema associate rosacea .</brief_summary>
	<brief_title>Efficacy Safety Study CD07805/47 Topical Gel Subjects With Facial Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<criteria>Male female , least 18 year age older . A clinical diagnosis rosacea . A Clinician Erythema Assessment ( CEA ) score 3 Screening Predose ( T0 ) Baseline/Day 1 . A Patient Self Assessment5 ( PSA5 ) score 3 Screening Predose ( T0 ) Baseline/Day 1 . A Patient Self Assessment11 ( PSA11 ) score 5 Screening Predose ( T0 ) Baseline/Day 1 . Three ( 3 ) facial inflammatory lesion . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sj√∂gren 's syndrome , depression . Known allergy sensitivities component study medication , include active gel ingredient , brimonidine tartrate . Intraocular pressure ( IOP ) measurement le 10 mm Hg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>